Antipsychotic drugs in Huntington’s disease

References

• Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.
   PubMed Web of Science ®Google Scholar
• Peavy GM, Jacobson MW, Goldstein JL, et al. Cognitive and functional decline in Huntington’s disease: dementia criteria revisited. Mov Disord. 2010;25(9):1163–1169.
   PubMed Web of Science ®Google Scholar
• Walker FO. Huntington’s disease. Lancet. 2007;369:218–228.
   PubMed Web of Science ®Google Scholar
• Van Duijn E, Craufurd D, Hubers A, et al. Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. 2014;85(12):1411–1418.
   PubMed Web of Science ®Google Scholar
• Paulsen JS, Hoth KF, Nehl C, et al. Critical periods of suicide risk in Huntington’s disease. Am J Psychiatry. 2005;162(4):725–731.
   PubMed Web of Science ®Google Scholar
• Farrer LA. Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet. 1986;24(2):305–311.
   PubMed Web of Science ®Google Scholar
• Mason SL, Barker RA. Advancing pharmacotherapy for treating Huntington’s disease: a review of the existing literature. Expert Opin Pharmacother. 2015;17:41–52.
   PubMed Web of Science ®Google Scholar
• Killoran A, Biglan KM. Current therapeutic options for Huntington’s disease: good clinical practice versus evidence-based approaches? Mov Disord. 2014;29:1404–1413.
   PubMed Web of Science ®Google Scholar
• Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for symptomatic treatment in Huntington’s disease. Cochrane Database Syst Rev. 2009;3:CD006456.
   PubMed Web of Science ®Google Scholar
• Burgunder JM, Guttman M, Perlman S, et al. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington’s disease. PLoS Curr. 2011;3:RRN1260.
   PubMedGoogle Scholar
• Gil J, Rego A. Mechanisms of neurodegeneration in Huntington’s disease. Eur J Neurosci. 2008;27(11):2803–2820.
   PubMed Web of Science ®Google Scholar
• Jacobs M, Hart EP, van Zwet EW, et al. Progression of motor subtypes in Huntington’s disease: a 6-year follow-up study. J Neurol. 2016. [Epub ahead of print].
   Web of Science ®Google Scholar
• Schwab LC, Garas SN, Drouin-Ouellet J, et al. Dopamine and Huntington’s disease. Expert Rev Neurother. 2015;15(4):445–458.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Miyasaki JM; American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79:597–603.
   PubMed Web of Science ®Google Scholar
• Priller J, Ecker D, Landwehrmeyer B, et al. A Europe-wide assessment of current medication choices in Huntington’s disease. Mov Disord. 2008;23(12):1788.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11(11):1509–1523.
   PubMed Web of Science ®Google Scholar
• Girotti F, Carella F, Scigliano G, et al. Effect of antipsychotic treatment on involuntary movements and motor performances in Huntington’s disease. J Neurol Neurosurg Psychiatry. 1984;47:848–852.
   PubMed Web of Science ®Google Scholar
• Barr AN, Fischer JH, Koller WC, et al. Serum haloperidol concentration and choreiform movements in Huntington’s disease. Neurology. 1988;38:84–88.
   PubMed Web of Science ®Google Scholar
• Koller WC, Trimble J. The gait abnormality of Huntington’s disease. Neurology. 1985;35(10):1450–1454.
   PubMed Web of Science ®Google Scholar
• Giménez-Roldán S, Mateo D. [Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements]. Neurologia. 1989;4:282–287. Spanish.
   PubMedGoogle Scholar
• Leonard DP, Kidson MA, Brown JG, et al. A double blind trial of lithium carbonate and haloperidol in Huntington’s chorea. Aust N Z J Psychiatry. 1975;9:115–118.
   PubMed Web of Science ®Google Scholar
• Benchoua A, Trioulier Y, Diguet E, et al. Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum Mol Genet. 2008;17:1446–1456.
   PubMed Web of Science ®Google Scholar
• Charvin D, Roze E, Perrin V, et al. Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo. Neurobiol Dis. 2008;29(1):22–29.
   PubMed Web of Science ®Google Scholar
• Lauterbach EC. Neuroprotective effects of psychotropic drugs in Huntington’s disease. Int J Mol Sci. 2013;14:22558–22603.
   PubMed Web of Science ®Google Scholar
• Tarighati S, A’Brook MF. Trifluperidol in Huntington’s chorea. Lancet. 1968;2(7565):458–459.
   PubMedGoogle Scholar
• Lyon RLL. Drug treatment of Huntington’s chorea: a trial with thiopropazate. BMJ. 1962;1:1308–1310.
   PubMedGoogle Scholar
• Bruyn GW. Thiopropazatedihydrochloride (Dartal) in the treatment of Huntington’s chorea. Psychiatr Neurol Neurochir. 1962;65:430–438.
   PubMedGoogle Scholar
• Heathfield KWG. Huntington’s chorea: a centenary review. Postgrad Med J. 1973;49:32–45.
   PubMed Web of Science ®Google Scholar
• McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet. 1974;1(7848):104.
   PubMed Web of Science ®Google Scholar
• Caine ED, Shoulson I. Psychiatric syndromes in Huntington’s disease. Am J Psychiatry. 1983;140:728–733.
   PubMed Web of Science ®Google Scholar
• Korenyi C, Whittier JR. Drug treatment in 117 cases of Huntington’s disease with special reference to fluphenazine (Prolixin). Psychiatr Q. 1967;41:203–210.
   PubMed Web of Science ®Google Scholar
• Terrence CF. Fluphenazinedecanoate in the treatment of chorea: a double-blind study. Curr Ther Res ClinExp. 1976;20:177–183.
   PubMed Web of Science ®Google Scholar
• Merskey H, Rice T, Troupe A. An investigation of some therapeutic and physiological effects of perphenazine in Huntington’s chorea. Psychopharmacologia. 1961;2:436–445.
   PubMed Web of Science ®Google Scholar
• Loeb C, Roccatagliata G, Medica GL, et al. Levodopa and Huntington’s chorea. J Neurol Neurosurg Psychiatry. 1976;39(10):958–961.
   PubMed Web of Science ®Google Scholar
• Riser M, Gayral L, Stern H, et al. [Treatment of Huntington’s chorea with chlorpromazine (largactil) and thioridazine (melleril)]. Rev Otoneuroophtalmol. 1959;31:498–501. French.
   PubMedGoogle Scholar
• Cohen NH. The treatment of Huntington’s chorea with trifluoperazine (stelazine). JNMD. 1962;134:62–71.
   PubMed Web of Science ®Google Scholar
• Joncev V, Mitkov V. Treatment of choreich hyperkinesias with thioproperazine (Majeptil). Folia Med. 1971;13(6):339–344.
   Google Scholar
• Fog R, Pakkenberg H. Combined nitoman-pimozide treatment of Huntington’s chorea and other hyperkinetic syndromes. Acta Neurol Scand. 1970;46:249–251.
   PubMed Web of Science ®Google Scholar
• McArthur AW, Pollock M, Smidt NA. Combined therapy with tetrabenazine and pimozide in Huntington’s chorea: pilot study. N Z Med J. 1976;83:114–116.
   PubMed Web of Science ®Google Scholar
• Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20:173–196.
   PubMed Web of Science ®Google Scholar
• Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington’s disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1984;47(8):844–847.
   PubMed Web of Science ®Google Scholar
• Reveley MA, Dursun SM, Andrews H. A comparative trial use of sulpiride and risperidone in Huntington’s disease: a pilot study. J Psychopharmacol. 1996;10(2):162–165.
   PubMed Web of Science ®Google Scholar
• Dursun SM, Andrews H, Reveley MA. Computerised continuous assessment of abnormal involuntary movements in Huntington’s disease; improvement by sulpiride. Br J ClinPharmacol. 1994;37:503P–504P.
   Google Scholar
• Saft C, Andrich J, Kraus PH, et al. Amisulpiride in Huntington’s disease. PsychiatrPrax. 2005;32(7):363–366.
   Google Scholar
• Roos RA, Buruma OJ, Bruyn GW, et al. Tiapride in the treatment of Huntington’s chorea. Acta Neurol Scand. 1982;65(1):45–50.
   PubMed Web of Science ®Google Scholar
• Quinn N, Marsden CD. Tiapride in 12 Huntington’s disease patients. J Neurol Neurosurg Psychiatry. 1985;48:292.
   PubMed Web of Science ®Google Scholar
• Deroover J, Baro F, Bourguignon RP, et al. Tiapride versus placebo: a double-blind comparative study in the management of Huntington’s chorea. Curr Med Res Opin. 1984;9:329–338.
   PubMed Web of Science ®Google Scholar
• Shoulson I. Huntington’s disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology. 1981;31:1333–1335.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Wenning GK. Pharmacological management of Huntington’s disease: an evidence-based review. Curr Pharm Des. 2006;12:2701–2720.
   PubMed Web of Science ®Google Scholar
• DeLeon A, Patel NC, Lynn Crismon M. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649–666.
   PubMed Web of Science ®Google Scholar
• Han M, Huang XF, Deng C. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropharmacol. 2009;10:1–12.
   Google Scholar
• Lin W-C, Chou Y-H. Aripiprazole effects on psychosis and chorea in a patient with Huntington’s disease. Am J Psychiatry. 2008;165:1207–1208.
   PubMed Web of Science ®Google Scholar
• Yavuz KF, Ulusoy S, Alnıak İ. Aripiprazole treatment for choreoathetoid and psychotic symptoms of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2013;25(2):E31–E31.
   PubMed Web of Science ®Google Scholar
• Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington’s disease: a case series. Neuropsychiatr Dis Treat. 2009;5:1–4.
   PubMed Web of Science ®Google Scholar
• Brusa L, Orlacchio A, Moschella V, et al. Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord. 2009;24:126–129.
   PubMed Web of Science ®Google Scholar
• Meco G, Bonifati V, Alessandri A, et al. Risperidone in Huntington’s disease (letter). Human Psychopharmacol. 1995;10:353–354.
   Web of Science ®Google Scholar
• Parsa MA, Szigethy E, Voci JM, et al. Risperidone in treatment of choreoathetosis of Huntington’s disease. J Clin Psychopharmacol. 1997;17:134–135.
   PubMed Web of Science ®Google Scholar
• Dallocchio C, Buffa C, Tinelli C, et al. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol. 1999;19:101–103.
   PubMed Web of Science ®Google Scholar
• Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington’s disease. Eur J Neurol. 2002;9(2):182–183.
   PubMed Web of Science ®Google Scholar
• Duff K, Beglinger LJ, O’Rourke ME, et al. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington’s disease. Ann Clin Psychiatry. 2008;20(1):1–3.
   PubMed Web of Science ®Google Scholar
• Caine ED, Polinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry. 1979;136:317–320.
   PubMed Web of Science ®Google Scholar
• Bonuccelli U, Ceravolo R, Maremmani C, et al. Clozapine in Huntington’s chorea. Neurology. 1994;44:821–823.
   PubMed Web of Science ®Google Scholar
• Van Vugt JPP, Siesling S, Vergeer M, et al. Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry. 1997;63:35–39.
   PubMed Web of Science ®Google Scholar
• Dipple HC. The use of olanzapine for movement disorder in Huntington’s disease: a first case report. J Neurol Neurosurg Psychiatry. 1999;67:123–124.
   PubMed Web of Science ®Google Scholar
• Grove VE Jr, Quintanilla J, DeVaney GT. Improvement of Huntington’s disease with olanzapine and valproate. N Engl J Med. 2000;343:973–974.
   PubMed Web of Science ®Google Scholar
• Squitieri F, Cannella M, Porcellini A, et al. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:69–72.
   PubMedGoogle Scholar
• Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington’s disease: an open label study. Clin Neuropharmacol. 2002;25:263–265.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Niederwieser G. Quetiapine in Huntington’s disease: a first case report. J Neurol. 2002;249:1114–1115.
   PubMed Web of Science ®Google Scholar
• Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington’s disease. Psychosomatics. 2006;47:70–72.
   PubMed Web of Science ®Google Scholar
• Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother. 2002;36:839–851.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Mayr BM, Niederwieser G, et al. Ziprasidone in Huntington’s disease: the first case reports. J Psychopharmacol. 2003;17:459–460.
   PubMed Web of Science ®Google Scholar
• Konopaske GT, Dorph-Petersen K-A, Sweet RA, et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry. 2008;63:759–765.
   PubMed Web of Science ®Google Scholar
• Ma D, Chan MK, Lockstone HE, et al. Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J Proteome Res. 2009;8(7):3284–3297.
   PubMed Web of Science ®Google Scholar
• Ebdrup BH, Nørbak H, Borgwardt S, et al. Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review. Curr Med Chem. 2013;20(3):438–447.
   PubMed Web of Science ®Google Scholar
• Tedroff J, Waters S, Barker R, et al.; on behalf of the EHDN Registry Study Group. Antidopaminergic medication is associated with more rapidly progressive Huntington’s disease. J Huntingtons Dis 2015;4(2):131–140.
   PubMed Web of Science ®Google Scholar
• Désaméricq G, Dolbeau G, Verny C, et al. Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort. PLoS One. 2014;9(1):e85430.
   PubMed Web of Science ®Google Scholar
• Squitieri F, de Yebenes JG. Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date. Drug Des Devel Ther. 2015;9:5827–5833.
   PubMed Web of Science ®Google Scholar
• Lundin A, Dietrichs E, Haghighi S, et al. Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington’s disease. Clin Neuropharmacol. 2010;33(5):260–264.
   PubMed Web of Science ®Google Scholar
• de Yebenes JG, Landwehrmeyer B, Squitieri F, et al.; for the MermaiHD study investigators. Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10(12):1049–1057.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group HART Investigators. A randomized, double- blind, placebo-controlled trial of pridopidine in Huntington’s disease. Mov Disord. 2013;28(10):1407–1415.
   PubMed Web of Science ®Google Scholar
• Landwehrmeyer B, Marder K, BillmannRonn B, et al. Effects of the dopaminergic stabilizer pridopidine on motor symptoms in Huntington’s disease: a meta-analysis. Presented At: World Congress on Huntington Disease; 2011 Sep 11–14; Melbourne (Australia).
   Google Scholar
• Neurodegenerative disease: pridopidine for Huntington disease falls short of primary efficacy end point in phase III trial. Nat Rev Neurol. 2011;8(1):4–4.
   PubMedGoogle Scholar
• Reilmann R. The pridopidine paradox in Huntington’s disease. Mov Disord. 2013;28(10):1321–1324.
   PubMed Web of Science ®Google Scholar